SCYNEXIS (SCYX) to Release Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect SCYNEXIS to post earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. The firm had revenue of $0.98 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Trading Up 1.9 %

SCYX opened at $1.07 on Thursday. The stock has a market capitalization of $41.71 million, a PE ratio of -1.45 and a beta of 1.67. SCYNEXIS has a 1-year low of $0.82 and a 1-year high of $3.07. The firm has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.24.

Analyst Ratings Changes

Separately, StockNews.com cut shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.